BUD27 Antibody

What is BUD27 and why is it significant in molecular biology research?

BUD27 is a member of the prefoldin-like (PFD) family of ATP-independent molecular chaperones, also called unconventional prefoldin Rpb5 interactor. The significance of BUD27 stems from its unique role as the first identified protein that participates in the biogenesis of all three eukaryotic RNA polymerases (I, II, and III). Studies have demonstrated that BUD27 mediates the assembly of these transcriptional complexes in Saccharomyces cerevisiae, particularly through its interaction with Rpb5 and Rpb6, two common subunits shared by all three RNA polymerases . This positions BUD27 as a critical node in the regulation of transcription across multiple polymerase systems, making it an important target for fundamental research into gene expression mechanisms.

How does BUD27 interact with the RNA polymerase machinery?

BUD27 physically interacts with multiple components of all three RNA polymerases. Immunoprecipitation studies and protein identification by mass spectrometry have revealed that BUD27 associates with various RNA polymerase subunits. Specifically, TAP purification experiments have shown that BUD27 interacts with Rpa190, Rpa135, and Rpa49 (RNA pol I); Rpc160 and Rpc128 (RNA pol III); Rpc40 (RNA pol I and III); Rpb1 (RNA pol II); and Rpb10 and Rpb5 (RNA pol I, II, and III) .

The most important interaction appears to be with Rpb5, a subunit common to all three RNA polymerases. BUD27 plays a critical role in facilitating the correct assembly of Rpb5 and Rpb6 into the polymerase complexes. When BUD27 is absent, the amount of Rpb5 and Rpb6 incorporated into the RNA polymerase complexes significantly decreases, indicating that BUD27 is essential for the proper assembly of functional RNA polymerases .

What detection methods can be used with BUD27 antibodies?

BUD27 antibodies can be effectively utilized in several detection methods for molecular biology research:

• Western Blotting: BUD27 antibodies have been successfully used to detect the presence of BUD27 in whole-cell extracts, chromatin fractions, and immunoprecipitated complexes. When evaluating RNA polymerase assembly, western blotting with BUD27 antibodies can help assess the association of BUD27 with polymerase components .

• Immunoprecipitation: BUD27 antibodies can be used to pull down BUD27 and its associated proteins. This technique has been instrumental in identifying the protein interactions of BUD27, particularly with RNA polymerase subunits .

• Immunocytochemistry: Similar to immunolocalization experiments performed with RNA polymerase subunits, BUD27 antibodies can be used to visualize the subcellular localization of BUD27 protein in fixed cells .

• Chromatin Immunoprecipitation (ChIP): Although not explicitly mentioned in the provided sources, BUD27 antibodies could potentially be used in ChIP experiments to investigate the association of BUD27 with specific genomic regions, particularly at transcriptionally active sites.

How do BUD27 antibodies help elucidate the role of BUD27 in RNA polymerase assembly?

BUD27 antibodies serve as critical tools for investigating the complex role of BUD27 in RNA polymerase assembly through several sophisticated experimental approaches:

BUD27 antibodies enable researchers to perform reciprocal co-immunoprecipitation experiments that have revealed crucial insights into the assembly pathway of RNA polymerases. For instance, when RNA polymerase II is immunoprecipitated using anti-Rpb1 antibodies from wild-type and Δbud27 mutant strains, the subsequent immunoblotting with antibodies against various polymerase subunits reveals significant differences in the composition of the complexes. Specifically, in Δbud27 mutants, the amount of Rpb5 and Rpb6 associated with the largest subunits of all three RNA polymerases is substantially decreased, while the associations between other subunits remain largely unaffected .

This selective defect in Rpb5 and Rpb6 incorporation provides strong evidence that BUD27 specifically facilitates the assembly of these common subunits into the polymerase complexes. Importantly, these experiments have demonstrated that BUD27 is not merely involved in the nuclear transport of RNA polymerases, as previously hypothesized, but rather plays a direct role in their cytoplasmic assembly .

What are the considerations for specificity when using BUD27 antibodies in cross-species research?

When using BUD27 antibodies across different species, researchers must carefully consider several specificity issues:

• Sequence conservation: While the function of BUD27/URI appears to be conserved from yeast to humans, there are significant differences in protein sequence that may affect antibody recognition. Researchers should verify the degree of conservation in the epitope regions targeted by their antibodies.

• Cross-reactivity testing: Before using BUD27 antibodies developed against one species in experiments with another species, thorough cross-reactivity testing is essential. This typically involves western blotting against purified proteins or cell lysates from the target species.

• Validation in knockout/knockdown models: The gold standard for confirming antibody specificity is testing in systems where the target protein has been deleted or depleted. For cross-species work with BUD27 antibodies, validation in Δbud27 yeast strains or URI-knockdown human cell lines should be performed .

• Domain-specific antibodies: BUD27/URI contains multiple functional domains, including the Rpb5-binding domain and the prefoldin-like domain. Antibodies targeting different domains may be more or less conserved across species, and domain-specific antibodies can help dissect the role of individual functional regions in different experimental contexts .

How can BUD27 antibodies be used to investigate its role in transcriptional regulation through the TOR cascade?

BUD27 antibodies provide powerful tools for investigating the connection between BUD27 and the TOR (Target of Rapamycin) signaling pathway in transcriptional regulation:

• Chromatin Association Analysis: BUD27 antibodies can be used in chromatin fractionation experiments followed by western blotting to assess how treatments affecting TOR signaling (such as rapamycin treatment or nutrient deprivation) impact the association of BUD27 with chromatin. This approach can reveal whether BUD27's interaction with transcriptional machinery is regulated by the TOR pathway .

• Co-immunoprecipitation Under TOR Modulation: Researchers can use BUD27 antibodies for immunoprecipitation experiments under conditions of TOR activation or inhibition to identify changes in BUD27-associated protein complexes, providing insights into how TOR signaling influences BUD27's interactions with RNA polymerases and other transcriptional regulators .

• ChIP-Seq Analysis: BUD27 antibodies can be employed in chromatin immunoprecipitation followed by sequencing (ChIP-Seq) to map genome-wide binding sites of BUD27 under different TOR signaling conditions. This can identify specific genes or genomic regions where BUD27 mediates TOR-dependent transcriptional regulation.

• Phosphorylation Status Detection: By combining BUD27 immunoprecipitation with phospho-specific detection methods, researchers can investigate whether BUD27 is directly phosphorylated in response to TOR signaling, potentially revealing a direct mechanistic link between TOR cascade and BUD27 function .

What are the optimal conditions for using BUD27 antibodies in immunoprecipitation experiments?

Based on successful immunoprecipitation protocols from published research on BUD27/RNA polymerase interactions, the following conditions are recommended:

Lysis Buffer Composition:

Critical Protocol Steps:

• Cross-linking (optional): For detecting transient interactions, consider using a reversible cross-linker like DSP (dithiobis[succinimidyl propionate]) at 1-2 mM for 30 minutes at room temperature.

• Pre-clearing: Incubate lysates with protein A/G beads for 1 hour at 4°C to reduce non-specific binding.

• Antibody incubation: Use 2-5 μg of BUD27 antibody per 1 mg of total protein lysate, incubating overnight at 4°C with gentle rotation.

• Washing: Perform at least 4-5 washes with lysis buffer containing reduced detergent (0.1%) to remove non-specific interactions while preserving specific ones.

• Elution: For native elution, consider using excess epitope peptide. For denaturing elution, use SDS sample buffer heated to 95°C for 5 minutes .

These conditions have been demonstrated to successfully preserve the interactions between BUD27 and RNA polymerase subunits, as evidenced by the co-purification of multiple polymerase components in published TAP purification experiments .

What controls should be included when using BUD27 antibodies for experimental validation?

When designing experiments with BUD27 antibodies, the following controls are essential for ensuring reliability and interpretability of results:

For Western Blotting:

• Positive control: Include lysate from cells known to express BUD27, such as wild-type yeast or human cell lines.

• Negative control: Include lysate from BUD27 knockout (Δbud27) or knockdown cells to confirm antibody specificity.

• Loading control: Use antibodies against a housekeeping protein (e.g., tubulin, GAPDH) to normalize protein levels across samples.

• Molecular weight marker: Include to confirm the expected size of BUD27 (approximately 54 kDa in yeast, 60 kDa in humans) .

For Immunoprecipitation:

• IgG control: Include a non-specific IgG antibody from the same species as the BUD27 antibody to assess non-specific binding.

• Bead-only control: Include a sample with beads but no antibody to assess direct binding of proteins to the beads.

• Input sample: Always include an aliquot of the starting material (typically 5-10%) to assess immunoprecipitation efficiency.

• Reciprocal IP: When studying interactions, perform reverse immunoprecipitation using antibodies against the putative interacting partner .

For Immunocytochemistry/Immunofluorescence:

• Secondary antibody-only control: Omit the primary antibody to assess background from the secondary antibody.

• Peptide competition: Pre-incubate the BUD27 antibody with excess antigen peptide to confirm specificity of staining.

• Knockout/knockdown cells: Include BUD27-depleted cells as a negative control .

For ChIP Experiments:

• IgG control: Use non-specific IgG to establish background enrichment levels.

• Positive genomic region: Include a genomic region known to be associated with RNA polymerases.

• Negative genomic region: Include a genomic region not expected to be associated with active transcription.

How can BUD27 antibodies be optimized for detection of protein-protein interactions with RNA polymerase subunits?

To maximize the detection of BUD27 interactions with RNA polymerase subunits, consider these optimization strategies:

• Cross-linking optimization: Test different cross-linkers (DSP, formaldehyde, or BS3) at various concentrations and incubation times to stabilize transient interactions. For example, 1% formaldehyde for 10 minutes at room temperature has been effective for RNA polymerase complex stabilization .

• Buffer composition adjustments:

  • Salt concentration: Test a range from 100-300 mM NaCl to find the optimal ionic strength that preserves specific interactions while reducing background.

  • Detergent type and concentration: Compare non-ionic detergents (NP-40, Triton X-100) with ionic detergents (deoxycholate) at different concentrations to optimize solubilization without disrupting interactions.

  • Stabilizing agents: Include 5-10% glycerol and 1-5 mM MgCl₂ to stabilize polymerase complexes .

• Sequential immunoprecipitation: For detecting specific subcomplexes, consider tandem immunoprecipitation:

  • First IP: Use BUD27 antibody to pull down all associated complexes

  • Elution: Gentle elution with peptide competition

  • Second IP: Use antibody against specific RNA polymerase subunit (e.g., Rpb1, Rpa190, or Rpc160)
    This approach, similar to the TAP purification method described in the research, can significantly increase specificity .

• Mass spectrometry-compatible protocols: When planning to identify novel interactions:

  • Avoid detergents incompatible with MS (e.g., SDS)

  • Consider on-bead digestion protocols

  • Use SILAC or TMT labeling to quantitatively compare interactions between wild-type and mutant conditions .

What are common issues when using BUD27 antibodies and how can they be resolved?

Issue: Weak or no signal in western blotting

Issue: Multiple bands or unexpected band size

Issue: High background in immunoprecipitation

Issue: Inability to detect BUD27-RNA polymerase interactions

How can conflicting results between different detection methods using BUD27 antibodies be reconciled?

When facing discrepancies between different detection methods using BUD27 antibodies, consider these systematic approaches for reconciliation:

• Methodological differences assessment:

  • Epitope accessibility: Different experimental conditions may expose different epitopes. For example, native IP may preserve conformational epitopes detected by certain antibodies but lost in denaturing western blots.

  • Protein complex stability: Some BUD27 interactions might be detectable by co-IP but not by western blotting after gel electrophoresis due to complex dissociation during SDS-PAGE.

  • Subcellular localization artifacts: Immunofluorescence and subcellular fractionation may give conflicting results due to extraction conditions affecting BUD27 localization .

• Systematic validation approach:

  • Use multiple antibodies: Test antibodies recognizing different BUD27 epitopes to confirm observations.

  • Combine techniques: For example, validate immunofluorescence observations with biochemical fractionation followed by western blotting.

  • Tagged protein validation: Compare results from antibody-based detection with results using tagged BUD27 versions (such as BUD27-TAP or BUD27-GFP) .

• Biological conditions consideration:

  • Cell cycle effects: BUD27 localization and interactions may vary throughout the cell cycle. Synchronize cells to eliminate this variable.

  • Stress responses: RNA polymerase assembly and nuclear import are affected by various cellular stresses. Control environmental conditions carefully.

  • Growth phase effects: Compare results from cells in different growth phases, as BUD27's role in ribosome biogenesis suggests growth-dependent functions .

• Quantitative reconciliation:

  • Create a comparative table documenting the conditions of each experiment (buffers, detergents, salt concentration)

  • Score interaction strength or localization patterns quantitatively across methods

  • Look for patterns that explain discrepancies, such as detergent sensitivity indicating weak interactions

How might novel BUD27 antibodies advance our understanding of RNA polymerase assembly?

Development of new specialized BUD27 antibodies could significantly advance our understanding of RNA polymerase assembly in several ways:

• Domain-specific antibodies: Creating antibodies that specifically recognize the Rpb5-binding domain of BUD27 versus its prefoldin-like domain would help dissect the functional contributions of each domain to RNA polymerase assembly. Research has shown that the Rpb5-binding domain is necessary for RNA polymerase biogenesis, while the role of the prefoldin-binding domain remains less clear .

• Conformation-specific antibodies: Developing antibodies that recognize specific conformational states of BUD27 could reveal whether BUD27 undergoes structural changes during its assembly function. Such antibodies could help identify intermediate states in the assembly process.

• Phospho-specific antibodies: Given BUD27's connection to the TOR signaling pathway, phospho-specific antibodies could determine if BUD27 is directly regulated by phosphorylation and how this affects its role in RNA polymerase assembly .

• Cross-species antibodies: Well-validated antibodies that recognize conserved epitopes in both yeast BUD27 and human URI would facilitate comparative studies to determine the evolutionary conservation of assembly mechanisms across eukaryotes. Current evidence suggests the role of URI is conserved in humans .

• Proximity-labeling compatible antibodies: Antibodies optimized for techniques like BioID or APEX2 proximity labeling could map the spatial and temporal dynamics of BUD27 interactions during RNA polymerase assembly in living cells.

What experimental designs using BUD27 antibodies could best elucidate its role in the TOR signaling cascade?

To investigate BUD27's role in the TOR signaling cascade, the following experimental designs using BUD27 antibodies would be particularly informative:

• Phosphoproteomics after TOR modulation:

  • Immunoprecipitate BUD27 from cells treated with TOR inhibitors (rapamycin) versus activators (amino acids, insulin)

  • Analyze phosphorylation changes by mass spectrometry

  • Identify specific phosphosites that respond to TOR signaling

• ChIP-Seq under TOR modulation:

  • Perform ChIP-Seq with BUD27 antibodies in cells under normal, TOR activation, and TOR inhibition conditions

  • Map changes in genomic binding sites

  • Correlate with transcriptional changes of ribosomal genes and RNA polymerase subunits

  • Integrate with RNA polymerase occupancy data

• BUD27 complex dynamics analysis:

  • Use time-course immunoprecipitation after TOR inhibition/activation

  • Monitor changes in BUD27 interaction partners over time

  • Develop a temporal map of how TOR signaling affects BUD27's association with RNA polymerases and ribosome biogenesis factors

• Nutrient-dependent subcellular localization:

  • Use immunofluorescence with BUD27 antibodies to track localization changes under different nutrient conditions

  • Correlate with TOR activity markers

  • Compare with mutants in the TOR pathway

  • Quantify nuclear/cytoplasmic ratios under different conditions

• Conditional mutant analysis:

  • Generate yeast strains with temperature-sensitive BUD27 mutations

  • Use BUD27 antibodies to assess RNA polymerase assembly and chromatin association under permissive and non-permissive conditions

  • Compare with TOR pathway mutants to establish epistatic relationships